MIR503HG and ovarian cancer: As shown in Figure 8, MIR503HG inhibited SPI1-mediated transcriptional activation of TMEFF1 by binding to SPI1, and suppressed the expression of TMEFF1, thus hindering the progression of ovarian cancer.